Header Logo

Wajeeha Razaq

TitleProf,Asoc
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentMedicine Hematology/Oncology
AddressSOCC 6031
800 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Carter J, Pugh SL, Arring N, Littell RD, Page SJ, Rowland KM, Goodman JR, Razaq W, Siddique S, Borges M, Kachnic LA, Barton DL. NRG-CC004 ancillary data study-exploring the effect of bupropion on sexual desire in female cancer survivors with and without vulvovaginal symptoms. J Sex Med. 2024 08 01; 21(8):709-715. PMID: 38856026; PMCID: PMC11294673.
      Citations:    Fields:    Translation:Humans
    2. Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ? 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol. 2024 Jun 04; JCO2302344. PMID: 38833643.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Woodward A, Southard B, Chakraborty S, Bailey AO, Faria GNF, McKernan P, Razaq W, Harrison RG. Correction: annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer. Mol Biomed. 2024 Apr 02; 5(1):16. PMID: 38564119; PMCID: PMC10987452.
      Citations:    
    4. Woodward A, Southard B, Chakraborty S, Bailey AO, Faria GNF, McKernan P, Razaq W, Harrison RG. Annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer. Mol Biomed. 2024 Feb 19; 5(1):7. PMID: 38369647; PMCID: PMC10874913.
      Citations:    Translation:Humans
    5. Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Rimawi MF, Weiss A, Winer EP, Hunt KK, Perou CM, Ellis MJ, Partridge AH, Carey LA. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Jan 18. PMID: 38236590; PMCID: PMC10797521.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    6. Geyer CE, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balma?a J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, J?hannsson ??, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marm? F, Martinez de Due?as E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, ?panic T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ, OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early?breast cancer. Ann Oncol. 2022 Dec; 33(12):1250-1268. PMID: 36228963.
      Citations: 84     Fields:    Translation:HumansCellsCTClinical Trials
    7. Dennahy IS, Han Z, MacCuaig WM, Chalfant HM, Condacse A, Hagood JM, Claros-Sorto JC, Razaq W, Holter-Chakrabarty J, Squires R, Edil BH, Jain A, McNally LR. Nanotheranostics for Image-Guided Cancer Treatment. Pharmaceutics. 2022 Apr 22; 14(5). PMID: 35631503.
      Citations: 7     
    8. Shikdar S, Hall S, Taylor B, de Los Angeles J, Tahirkheli M, Zhao D, Razaq W. Evaluating the Response of Palbociclib on Progression-Free Survival in Hormone Receptor-Positive Metastatic Breast Cancer. Oncology. 2022; 100(6):337-343. PMID: 35344965.
      Citations:    Fields:    Translation:Humans
    9. Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). J Clin Oncol. 2022 03 20; 40(9):978-987. PMID: 34995128.
      Citations: 48     Fields:    Translation:Humans
    10. Shikdar S, Fowle E, Razaq H, Razaq W. Hormonal receptor evaluation in salivary duct adenocarcinoma. Oral Oncol. 2021 11; 122:105548. PMID: 34634668.
      Citations:    Fields:    Translation:Humans
    11. Carlson BW, Craft MA, Carlson JR, Razaq W, Deardeuff KK, Benbrook DM. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018 06; 40(3):325-336. PMID: 29804200.
      Citations: 14     Fields:    Translation:Humans
    12. Gutschenritter T, Machiorlatti M, Vesely S, Ahmad B, Razaq W, Razaq M. Outcomes and Prognostic Factors of Resected Salivary Gland Malignancies: Examining a Single Institution's 12-year Experience. Anticancer Res. 2017 09; 37(9):5019-5025. PMID: 28870928.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    13. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids. 2016 Dec 13; 5(12):e399. PMID: 27959340.
      Citations: 12     
    14. Kang SA, Blache CA, Bajana S, Hasan N, Kamal M, Morita Y, Gupta V, Tsolmon B, Suh KS, Gorenstein DG, Razaq W, Rui H, Tanaka T. Erratum to: The effect of soluble E-selectin on tumor progression and metastasis. BMC Cancer. 2016 06 28; 16(1):370. PMID: 27353033.
      Citations: 1     Fields:    
    15. Kang SA, Blache CA, Bajana S, Hasan N, Kamal M, Morita Y, Gupta V, Tsolmon B, Suh KS, Gorenstein DG, Razaq W, Rui H, Tanaka T. The effect of soluble E-selectin on tumor progression and metastasis. BMC Cancer. 2016 05 24; 16:331. PMID: 27220365.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    16. Kang SA, Tsolmon B, Mann AP, Zheng W, Zhao L, Zhao YD, Volk DE, Lokesh GL, Morris L, Gupta V, Razaq W, Rui H, Suh KS, Gorenstein DG, Tanaka T. Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice. Toxicol Appl Pharmacol. 2015 Aug 15; 287(1):86-92. PMID: 26048585.
      Citations: 10     Fields:    Translation:Animals
    17. Razaq W. Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med. 2013 Oct 14; 2(4):176-87. PMID: 26237142.
      Citations: 1     
    18. Razaq W, Goel A, Amin A, Grossbard ML. Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. Clin Lymphoma Myeloma. 2009 Jun; 9(3):E5-9. PMID: 19525185.
      Citations: 12     Fields:    Translation:HumansCells
    19. Razaq W, Beautyman E. Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide. Am J Ther. 2009 Jan-Feb; 16(1):68-70. PMID: 19142161.
      Citations: 1     Fields:    Translation:HumansCells
    20. Razaq W, Hyde P. Reversible peripartum cardiomyopathy in a patient with prior exposure to interferon. Am J Ther. 2006 Jul-Aug; 13(4):373-5. PMID: 16858174.
      Citations:    Fields:    Translation:Humans
    Razaq's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (106)
    Explore
    _
    Co-Authors (11)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _